Timeline Milestones

AprilThe Human Genome Project completes sequencing of the human genome, leading to important breakthroughs in the understanding and treating of genetic conditions

JulyElectric cars turn luxury with Tesla’s introduction of the roadster

JanuaryRovers 'Spirit' and 'Opportunity' land on Mars, leading to further evidence of water on the red planet

BioMarin files Naglazyme for regulatory approval in the United States and Europe

FebruaryHarvard student Mark Zuckerberg launches “The Facebook,” a new social networking site, from his dormitory room

MayNaglazyme is approved by the FDA, marking the company’s second approved treatment for MPS and first independently commercialized drug

MayJean-Jacques Bienaimé joins BioMarin as Chief Executive Officer and member of the Board of Directors

April‘Me at the Zoo’ becomes the first video posted to YouTube, revolutionizing how video content is exchanged online

JanuaryNaglazyme receives approval in Europe, prompting the company to establish commercial operations in Europe

OctoberAldurazyme receives marketing approval in Japan

MarchGlobal communication and news consumption changes forever with the launch of Twitter

NovemberBioMarin files an IND application to study pegvaliase for the treatment of PKU

MarchGalli North begins operations

DecemberThe FDA approves Kuvan for the treatment of PKU, marking the first approved treatment for the condition and the company’s third approved product

JuneApple reinvents the phone as it introduces the first iPhone, marking a convergence of computers and telephones, never to look back

DecemberThe world does not come to an end despite some belief that an apocalypse is destined for December 21, 2012

SeptemberKelly Clarkson beats Justin Guarini to win the first season of American Idol

AugustBioMarin completes acquisition of Glyko Biomedical

NovemberBarack Obama historically elected as the first African-American president of the United States

MarchNaglazyme is approved in Japan

NovemberBioMarin APAC site established in Hong Kong

DecemberKuvan is approved in Europe

September BioMarin and Genzyme join forces to commercialize Aldurazyme for MPS I

FebruaryDolly the Sheep makes her public debut as the world’s first cloned mammal

JuneJK Rowling releases “Harry Potter and the Philosopher's Stone,” the first novel of the series

1997

JanuaryWikipedia launches, marking the first online encyclopedia created and edited by volunteers around the world

2001

JulyBioMarin goes public on the NASDAQ and SIX Swiss Exchange with symbol “BMRN”

1999

SeptemberThe first clinical trial for Naglazyme begins, marking BioMarin's second MPS drug candidate

JanuaryBioMarin’s Galli manufacturing facility approved for operations

2000 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

MarchTitanic sweeps the Oscars with 11 Academy Awards, including Best Picture

OctoberDiscovery becomes first shuttle to dock with the international space station – a multi-national, permanent, orbiting research laboratory

MayReality TV becomes all the rage as “Survivor” makes its television debut

1998

March Chris Starr, Grant Dennison and John Klock incorporate BioMarin

see full prescribing information for boxed warning

NovemberBioMarin initiates the first Aldurazyme clinical trial for the treatment of MPS I

SeptemberGoogle opens its door, offering a new way to surf the internet

JuneAldurazyme is approved in Europe

AprilAldurazyme is approved by the FDA for the treatment of MPS I, becoming the first treatment for an MPS condition in the world

FebruaryNaglazyme is approved in Brazil

AprilBioMarin initiates a Phase I/II clinical trial evaluating VIMIZIM for the treatment of MPS IVA, or Morquio A syndrome

AprilKuvan is approved in Canada

JanuaryCaptain Sully wins America's heart as he safely guides US Airways Flight 1549 to safety, saving 155 passengers in an event now known as "The Miracle on the Hudson"

MayFirdapse launches in Europe

AprilApple releases the first iPad, taking touch screen technology to a new level

NovemberThe San Francisco Giants win the World Series,its first in 56 years

iPad

DecemberBioMarin announces clinical program for BMN-190 for the treatment of CLN2 disease, a form of Batten disease

JuneBioMarin purchases Shanbally manufacturing plant in Ireland

NovemberBioMarin’s expansion of Galli East approved for manufacturing

SeptemberThe first trial for BMN-111 begins, evaluating the therapy for the treatment of achondroplasia

AprilPrince William and Kate Middleton marry at Westminster Abbey in London

NovemberFDA Advisory Committee recommends the FDA approve VIMIZIM for the treatment of Morquio A

MarchPope Francis becomes the first non-European Pope in more than 500 years

FebruaryVIMIZIM receives FDA approval for Morquio A syndrome, marking the company’s fifth approved product and the first treatment for the condition

AprilVIMIZIM receives approval in Europe

DecemberVIMIZIM is approved in Japan and Australia

JulyThe ALS Ice Bucket Challenge goes viral, raising $41.8 million in donations

SeptemberThe first Hemophilia A patient is enrolled in a phase 1/2 trial of BMN 270, a gene therapy drug candidate

OctoberBioMarin acquires global rights to Kuvan from Merck Serono, expanding its commitment to PKU patients around the world

DecemberStar Wars returns with The Force Awakens

JuneWith 73 wins, the Golden State Warriors break the NBA record for most combined wins in a single season

AprilThe first MPS IIIB patient is enrolled in a Phase 1/2 clinical trial evaluating BMN 250, marking the company’s focus for a fourth drug candidate for an MPS condition

JulyThe FDA accepts BLA for Brineura, assigning a review date for April 2017

AugustFor the third consecutive year, BioMarin ranks in the top 10 on Forbes "World's Most Innovative Companies" list

BMN250

BMN270

SeptemberBioMarin is named as one of the fastest drug developers in the industry by CenterWatch

JulyVIMIZIM is approved in Canada

BMN111

BMN190 September

The EMA validates the Marketing Authorization Application for Brineura

see full prescribing information for boxed warning

JanuaryIn 2017, BioMarin reaches its 2,017th commercial MPS patient

AprilBrineura is approved by the FDA as the first treatment for children with CLN2 disease, a form of Batten disease

JuneThe European Commission approved Brineura, the first treatment approved in the European Union for the treatment of CLN2

see full prescribing information for boxed warning